By Thomas Lee
A Food & Drug Administration panel unanimously recommended that the agency clear an MRI-friendly pacemaker developed by Medtronic Inc. (NYSE:MDT).
The panel voted 15-0 to green-light the company’s REVO Surescan pacemaker. The decision is not binding, but the agency almost always follows the panel’s recommendation.
Spokesman Chris Garland said Medtronic hopes the FDA will formally clear the device between May and October this year, during the first half of Medtronics’ fiscal 2011 year.